Abstract: A lipophilic copolymer including polar multi-blocks having general formula (I): [(ByAk)s]t(AjCm)??(I) wherein: B represents at least one monomer unit deriving from a lipophilic monomer having general formula (II): wherein: X represents a hydrogen atom; or a methyl group; R is selected from C1-C50 alkyl groups, linear or branched; A represents at least one monomer unit deriving from a polar monomer selected from: (a) compounds having general formula (III): wherein X represents a hydrogen atom or a methyl group and n represents an integer comprised between 0 and 4; (b) (meth)acrylamide or (meth)acrylamides substituted on the nitrogen atom with one or two C1-C4 alkyl groups linear or branched; (c) di-(C1-C4)-alkylamino-(C1-C4)-alkyl (meth)acrylates; C represents at least one monomer unit deriving from a polar polyfunctional monomer having general formula (IV): Z—(W)p??(IV) wherein: Z represents a group containing carbon, hydrogen and, optionally, oxygen;

Abstract: Hybrid concentrated photovoltaic device comprising: (i) at least one luminescent solar concentrator (LSC) having the shape of a polygonal, circular, or elliptical plate, comprising at least one photoluminescent compound having a spectral range of absorption and a spectral range of emission; (ii) at least one micrometric or sub-micrometric dielectric photonic structure, optically coupled to said luminescent solar concentrator (LSC), said micrometric or sub-micrometric dielectric photonic structure being able to induce diffusion and/or diffraction of sunlight, preferably diffraction, within said luminescent solar concentrator (LSC), in a spectral range where there is no absorption of said photoluminescent compound; (iii) at least one photovoltaic cell positioned on the outside of at least one side of said luminescent solar concentrator (LSC).

Abstract: The invention relates to microparticles that may be used for antigen delivery and vaccine immunization strategies. The invention in particular relates to microparticles that are useful in the prophylaxis and treatment of human immunodeficiency virus (HIV) infections.